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The use of antimicrobials in food animals creates an important source of antimicrobial-resistant bacteria that can spread to
humans through the food supply. Improved management of the use of antimicrobials in food animals, particularly reducing
the usage of those that are “critically important” for human medicine, is an important step toward preserving the benefits
of antimicrobials for people. The World Health Organization has developed and applied criteria to rank antimicrobials
according to their relative importance in human medicine. Clinicians, regulatory agencies, policy makers, and other stake-
holders can use this ranking when developing risk management strategies for the use of antimicrobials in food production
animals. The ranking allows stakeholders to focus risk management efforts on drugs used in food animals that are the most
important to human medicine and, thus, need to be addressed most urgently, such as fluoroquinolones, macrolides, and
third- and fourth-generation cephalosporins.
Antimicrobials decrease morbidity and mortality associated
with serious and life-threatening infections. Antimicrobial re-
sistance decreases the effectiveness of these drugs, increasing
the risk of morbidity and mortality in serious diseases and,
thus, compromising human health [1–6].
Antimicrobial resistance is an inevitable consequence of an-
timicrobial use. Poverty; suboptimal control of the sale, quality,
and use of antimicrobials; and poor sewage and water systems
are factors that contribute to the emergence and spread of
Received 12 December 2008; accepted 21 February 2009; electronically published 2 June
2009.
The content of this article does not necessarily reflect the views or policies of the
Department of Health and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the US Government.
World Health Organization meeting participants are listed at the end of text.
Reprints or correspondence: Dr. Peter Collignon, Infectious Diseases Unit and Microbiology
Dept., The Canberra Hospital, School of Clinical Medicine, Australian National University, P.O.
Box 11, Woden, ACT, 2607 Australia (peter.collignon@act.gov.au).
Clinical Infectious Diseases 2009; 49:132–41
 2009 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2009/4901-0015$15.00
DOI: 10.1086/599374
antimicrobial resistance. High rates of resistance have been re-
ported, even in Escherichia coli, one of the most common causes
of bacterial infection in people [7, 8]. Increasing levels of re-
sistance complicate the selection of empirical and definitive
antimicrobial therapy for serious bacterial infection. Some au-
thors have recommended broad-spectrum agents, such as car-
bapenems, as empirical therapy [9], but the collateral damage
to commensal and colonizing organisms is likely to accelerate
the development of multidrug resistance through the selection
and spread of bacteria that produce metallo-b-lactamases.
Food animals (e.g., chickens, cattle, turkeys, and pigs) are a
source for bacterial species that cause human infections, in-
cluding Campylobacter and Salmonella species. Commensal
bacteria, such as E. coli and Enterococcus, and the resistance
genes they carry, are transmitted to people via the food chain
or by direct exposure to animals [10–14]. The administration
of antimicrobials occurs in higher volumes among food ani-
mals, compared with people [14, 15]. The amount of anti-
microbial-resistant bacteria that develop are proportionate to
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the total volume of antimicrobials used, and the development
of resistance is affected by the ways in which the drugs are
used. In many countries, antimicrobial use in food animals
occurs in situations with little or no associated economic or
health benefits (e.g., growth promotion) while contributing to
the risk of antimicrobial resistance [16].
Antibiotic usage in food animals leads to the development
and spread of organisms that are resistant to fluoroquinolones,
third- and fourth-generation cephalosporins, and vancomycin,
among others. The relative contribution of foodborne trans-
mission to antimicrobial resistance in humans remains un-
known, but it is not zero and is likely more substantial than
is currently appreciated [10–14]. Humans are exposed to an-
timicrobial-resistant bacteria and resistance genes that are pres-
ent in the food chain. Some studies have suggested that the
majority of antibiotic-resistant E. coli carried by people may
have originated in food animals, especially chickens [12].
Mitigating the risks of antimicrobial resistance to human
health requires risk management strategies for the use of an-
timicrobials in animals. To decrease the development and
spread of antimicrobial-resistant foodborne bacteria, we must
reduce the use of antibiotics in food animals and decrease the
injudicious use of antimicrobials in human medicine. These
issues are of great importance for drugs that are critical to
human medicine.
The World Health Organization (WHO) has developed cri-
teria to rank antimicrobials according to their importance in
human medicine [17, 18]. These lists will be a component of
risk management strategies to mitigate the human health risks
associated with antimicrobial use in food animals. The WHO
lists help to prioritize resources that address the use in food
animals of the most critical antibiotics for humans. These lists
will help regulators and stakeholders determine which types of
antimicrobials could be used in food animal production and
determine how these antibiotics might be managed (e.g., sin-
gle animal therapy or mass treatment via water, prohibiting
extra-label use, etc.). The use of these lists will help preserve
the effectiveness of currently available antimicrobials. We pre-
sent the development, criteria, and content of these lists in this
paper.
WHAT ARE THE BACTERIA AND
ANTIMICROBIAL-RESISTANCE TRAITS OF
MOST CONCERN FROM FOOD ANIMALS?
Campylobacter and Salmonella. Campylobacter and non-ty-
phoid Salmonella species spread from animals to people via
food and water, particularly in developed countries. When an-
timicrobials are indicated for treatment of Salmonella infection
(e.g., bloodstream infections), clinicians often treat with fluo-
roquinolones and third-generation cephalosporins [19]. How-
ever, these same classes of antimicrobial agents are also ad-
ministered to food animals, which leads to the inevitable
development of resistant bacteria [20–26].
An increasing prevalence of Campylobacter that are resistant
to fluoroquinolones is associated with the use of this class of
drugs in food animals [20–26]. In countries where fluoro-
quinolones are banned or used sparingly in food animals (e.g.,
Sweden, Norway, and Australia), studies demonstrate a low
prevalence of fluoroquinolone-resistant Campylobacter [21, 25],
despite the use of fluoroquinolones in human medicine for 120
years. In countries where fluoroquinolones are or were fre-
quently used in food animals (e.g., Spain, China, and the United
States), higher rates of resistance are observed among isolates
from both food animals and humans [20–26]. In these latter
countries, high resistance rates developed very rapidly, but did
so only after the introduction of fluoroquinolones in food
animals.
Staphylococcus aureus. S. aureus causes infections in
many animals, including poultry, pigs, and cattle. In Europe,
the United States, and Canada, methicillin-resistant S. aureus
isolates have spread from food animals [27–30] and companion
animals to people [31, 32]. Although it currently represents a
low proportion of the total methicillin-resistant S. aureus in-
fections that occur in people, there are an increasing number
of reports of animal-derived methicillin-resistant S. aureus, es-
pecially from pigs, causing community-onset infection in
people.
E. coli. Antimicrobial resistance in E. coli is an increasing
problem [7, 8, 33–42], particularly in developing countries (e.g.,
China and Mexico) [7, 33] where strains that cause blood
stream infections are frequently multidrug resistant. The main
reservoir for E. coli is the gastrointestinal tract, where there is
a large turnover of E. coli each day [41]. Food is an important
vector for these organisms [10, 12, 13, 38, 39]. Food animals
likely contribute a substantial proportion of the E. coli in the
human gastrointestinal tract, including drug-resistant strains.
Although most strains of E. coli are relatively host specific,
various studies have demonstrated that drug-resistant strains
of animal origin (e.g., fluoroquinolone-resistant E. coli from
chickens) can either colonize or cause infection in humans [12,
13, 36, 38]. Human infections with bacteria that are resistant
to third-generation cephalosporins, fluoroquinolones, and/or
aminoglycosides are now widespread, and the number of such
infections is rapidly increasing in many countries [3].
Studies report an increasing frequency of community-ac-
quired infections due to extended-spectrum b-lactamase–pro-
ducing E. coli strains, despite the relatively infrequent use of
third- and fourth-generation injectable cephalosporins for
treating people in the community [33, 34, 37, 38]. Increasing
numbers of community-acquired, extended-spectrum b-lac-
tamase–producing E. coli are carried in the population. Re-
searchers have reported increasing frequencies of drug-resistant
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isolates in foods around the world. In Spain [38], studies found
similar bacteria in humans, food, animal farms, and sewage.
The use of third- and fourth-generation cephalosporins in food
animals select for undesired drug-resistance phenotypes in an-
imal bacteria, including selection of extended-spectrum b-lac-
tamase–producing strains [40–43]. Worldwide spread of these
highly drug-resistant bacteria and their genes (genes that en-
code CTX-M and CMY b-lactamases are transferable among
bacteria) is occurring.
Enterococcus. Enterococcus species, in particular Entero-
coccus faecium, are intrinsically resistant to a number of anti-
microbials, which limits treatment options for infection due to
these pathogens. The emergence of genetic determinants that
confer resistance to vancomycin can limit treatment options
still further [43].
WHO CLASSIFICATION ON THE CRITICAL
IMPORTANCE OF ANTIMICROBIALS USED IN
HUMAN MEDICINE
The Canberra meeting, 2005. In 2005, the WHO organized
a consultation in Canberra, Australia, to develop a list of crit-
ically important antimicrobial agents in human medicine [17].
This list was generated in an effort to provide a tool for de-
veloping risk-management strategies and focusing resources to
address antimicrobial use in agriculture and veterinary medi-
cine. Until that time, there had been no international consensus
on the classification of different groups of antibiotics in relation
to their importance to human medicine [3, 14, 15, 25, 26].
In developing the list, the consultants did not consider any
antimicrobial or class of antimicrobials used in human medi-
cine to be unimportant. Therefore, to categorize the relative
importance of these drugs in human medicine, they defined 3
categories of antimicrobials: critically important (table 1), highly
important (table 2), and important (table 3). The consultants
included comments in the tables in recognition of regional
factors that might affect the rankings, but these comments were
not meant to be exhaustive, and other regional factors may be
relevant. The purpose of the comments was to increase, not
decrease, the importance of drugs on the list on the basis of
these regional factors. An antimicrobial class is defined as a
group of agents with a similar mechanism of action, regardless
of chemical structure.
Each antimicrobial agent (or class) was assigned to 1 of the
3 categories of importance on the basis of 2 criteria: (1) the
agent or class is the sole therapy or one of few alternatives to
treat serious human disease; and (2) the antimicrobial agent
or class is used to treat diseases caused by organisms that may
be transmitted via nonhuman sources or diseases caused by
organisms that may acquire resistance genes from nonhuman
sources. Critically important antimicrobials are those that meet
both criteria. Highly important antimicrobials are those that
meet 1 of 2 criteria. Important antimicrobials are those that do
not meet either criteria.
The consultants considered it important to set ranking cri-
teria first to categorize drugs in a fair and impartial manner.
The consultants arrived at these criteria through discussion and
consensus. These criteria are based on sound scientific reason-
ing. For criterion 1, it is obvious that antimicrobials that are
one of few alternatives for treatment of serious diseases have
a critical place in human medicine. Criterion 2 grants greater
importance to antimicrobial agents that are used to treat dis-
eases caused by bacteria that can be transmitted from non-
human sources to humans. The panel did not suggest that the
transmission of such organisms or their genes must be proven,
but only that there is the potential for such transmission to
occur.
Tables 1, 2, and 3 outline the rankings of antimicrobials. The
tables list only the generic drug names of antimicrobials used
in humans. The tables show examples of members in each class,
but the list is not inclusive of all drugs. In most groups, similar
drugs are used in animals, for example, both enrofloxacin (a
fluoroquinolone) and tylosin (a macrolide) are used in food
animals (table 4). If resistance develops to 1 member of a class,
generally, all other members of that group are affected because
of cross-resistance. The WHO classification should be consid-
ered to be a core list of the most critical antimicrobial agents
globally [17, 18]. However, considerations such as cost and
availability of antimicrobials in various geographic areas and
local resistance rates could increase the ranking of some drugs.
For instance, an antimicrobial agent that is ranked highly im-
portant may become critically important in a particular region,
because that agent may be the sole agent available in that area.
The Copenhagen meeting, 2007. The WHO convened a
second meeting in Copenhagen, Denmark, in 2007 to re-eval-
uate the classification of antimicrobials and update the list on
the basis of recent developments [18]. Relatively few changes
were needed. The panel recommended the following changes:
• 1. Tigecycline (a new tetracycline-derivative with activity
against multidrug-resistant S. aureus and gram-negative bac-
teria) became available in 2005 and was categorized as crit-
ically important.
• 2. All penicillins (except for penicillins active against staph-
ylococcal organisms) were grouped together as a single class
and remained critically important.
• 3. The penicillins active against staphylococcal organisms
were moved from the important to the highly important cat-
egory, because there is now more evidence of the potential
transfer of S. aureus, including methicillin-resistant S. aureus,
from animals to humans.
• 4. Because of the evidence of transfer of flo genes and chlo-
ramphenicol-resistant Salmonella species from animals to hu-
Table 1. Critically important antimicrobials that are used in human medicine.
Antimicrobial class Antimicrobial(s) Criterion 1a Criterion 2b Comment(s)
Aminoglycosides Amikacin and arbekacin; gentamicin, netilmicin,
and tobramycin; and streptomycin
Yes Yes Limited therapy as part of treatment of enterococcal
endocarditis and MDR tuberculosis
Potential transmission of Enterococcus species, En-
terobacteriaceae (including Escherichia coli), and
Mycobacterium species from nonhuman sources.
Ansamycins Rifabutin, rifampin, and rifaximin Yes Yes Limited therapy as part of therapy of mycobacterial
diseases including tuberculosis and single drug
therapy may select for resistance
Potential transmission of Mycobacterium species
from nonhuman sources
Carbapenems and
other penems
Ertapenem, faropenem, imipenem, and
meropenem
Yes Yes Limited therapy as part of treatment of disease due
to MDR gram-negative bacteria
Potential transmission of Enterobacteriaceae, includ-
ing E. coli and Salmonella sprecies, from nonhu-
man sources
Cephalosporins, third
and fourth generation
Cefixime, cefotaxime, cefpodoxime, ceftazidime,
ceftizoxime, cefoperazone, cefoperazone-sul-
bactam, and ceftriaxone; cefepime, cefpirome,
and cefoselis
Yes Yes Limited therapy for acute bacterial meningitis and
disease due to Salmonella in children
Fourth-generation cephalosporins provide limited
therapy for empirical treatment of neutropenic pa-
tients with persistent fever
Potential transmission of Enterobacteriaceae, includ-
ing E. coli and Salmonella species, from nonhuman
sources
Glycopeptides Teicoplanin and vancomycin Yes Yes Limited therapy for infection due to MDR Staphylo-
coccus aureus and Enterococcus species
Potential transmission of Enterococcus species and
MDR S. aureus from nonhuman sources
Lipopeptides Daptomycin Yes Yes Limited therapy for infection due to MDR S. aureus
Potential transmission of Enterococcus species and
MDR S. aureus from nonhuman sources
Macrolides, including
14-, 15-, and 16-
membered com-
pounds, and
ketolides
Azithromycin, clarithromycin, erythromycin, mide-
camycin, roxithromycin, spiramycin, and
telithromycin
Yes Yes Limited therapy for infection due to Legionella, Cam-
pylobacter, and MDR Salmonella species
Potential transmission of Campylobacter species
from nonhuman sources
Oxazolidinones Linezolid Yes Yes Limited therapy for infection due to MDR S. aureus
and Enterococcus species
Potential transmission of Enterococcus species and
MDR S. aureus from nonhuman sources
Penicillins, including
natural penicillins,
aminopenicillins, and
antipseudomonals
Penicillin G, penicillin V, ampicillin, ampicillin-sul-
bactam, amoxicillin, amoxicillin-clavulanate, pi-
peracillin, piperacillin-tazobactam, azlocillin, car-
benicillin, mezlocillin, ticarcillin, and
ticarcillin-clavulanate
Yes Yes Limited therapy for syphilis (natural penicillins), Liste-
ria and Enterococcus species (aminopenicillins),
and MDR Pseudomonas species
(antipseudomonals)
Potential transmission of Enterococcus species, En-
terobacteriaceae (including E. coli), and Pseudo-
monas aeruginosa from nonhuman sources
Quinolones Cinoxacin, nalidixic acid, and pipemidic acid; cip-
rofloxacin, enoxacin, gatifloxacin, gemifloxacin,
levofloxacin, lomefloxacin, moxifloxacin, nor-
floxacin, ofloxacin, and sparfloxacin
Yes Yes Limited therapy for Campylobacter species, invasive
disease due to Salmonella species, and MDR Shi-
gella species infection
Potential transmission of Campylobacter species and
Enterobacteriaceae, including E. coli and Salmo-
nella species, from nonhuman sources
Streptogramins quinupristin-dalfopristin and pristinamycin Yes Yes Limited therapy for MDR Enterococcus faecium and
S. aureus infection
Potential transmission of Enterococcus species and
MDR S. aureus from nonhuman sources
Tetracyclines and
glycylcyclines
Tigecycline Yes Yes Limited therapy for infection due to MDR S. aureus
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Table 1. (Continued.)
Antimicrobial class Antimicrobial(s) Criterion 1a Criterion 2b Comment(s)
Drugs used solely to
treat tuberculosis or
other mycobacterial
diseases
Cycloserine, ethambutol, ethionamide, isoniazid,
para-aminosalicylic acid, and pyrazinamide
Yes Yes Limited therapy for tuberculosis and other disease
due to Mycobacterium species
For many of these drugs, single drug therapy may
select for resistance
Potential transmission of Mycobacterium species
from nonhuman sources
NOTE. From the World Health Organization meeting in Copenhagen, Denmark [18]. Both of the 2 criteria were met for classification as a highly important
antimicrobial. MDR, multidrug-resistant.
a Criterion 1: the agent or class is the sole therapy or one of few alternatives to treat serious human disease.
b Criterion 2: the antimicrobial agent or class is used to treat diseases caused by organisms that may be transmitted via nonhuman sources or diseases causes
by organisms that may acquire resistance genes from nonhuman sources.
mans, the amphenicols were moved from the important to
the highly important category.
• 5. Because of differing resistance mechanisms, the amino-
glycosides were divided into 2 groups. As a result, 2 ami-
noglycosides (kanamycin and neomycin) were moved from
the critically important to the highly important category.
• 6. Third- and fourth-generation cephalosporins were com-
bined in the tables, because the mechanisms of action and
antimicrobial resistance are similar.. The first- and second-
generation cephalosporins were also combined.
PRIORITIZATION WITHIN THE CRITICALLY
IMPORTANT CATEGORY
The WHO asked the consultants in Copenhagen to prioritize
agents within the critically important category, to assist the al-
location of resources toward agents for which risk management
of antimicrobial resistance is needed most urgently. The con-
sultants considered drugs to be of greatest priority if: (1) there
are relatively large absolute numbers of people affected by dis-
eases for which the drug is the sole alternative or one of few
alternative therapies; (2) the overall frequency of use of the
drugs in human medicine for any reason (whether appropriate
or inappropriate) is relatively large; and (3) the drug is used
to treat disease due to pathogens for which there is evidence
regarding transmission of bacteria or their genes from non-
human sources to humans (i.e., E. coli, Campylobacter species,
and Salmonella species).
This prioritization resulted in the designation of quinolones,
third- and fourth-generation cephalosporins, and macrolides
as the classes for which risk-management strategies are needed
most urgently. In the future, the WHO might consider con-
vening a meeting of stakeholders to discuss the progress of
various government agencies in addressing risk-management
strategies for the use of these antimicrobials. In addition, there
should be reliable, unbiased measures of the impact on resis-
tance of any prudent-use guidelines or principles that are
adopted by veterinary medical associations or animal produc-
tion groups.
The expert panel emphasized that prioritization of these 3
classes of drugs should not minimize the importance of other
drugs that are categorized as critically important on the list.
Furthermore, any use of the ranking should consider regional
differences, as noted above. Therefore, drugs that are not con-
sidered to be critically important in the list might be critically
important in some developing countries (e.g., the importance
of chloramphenicol might be increased because of a lack of
access to cephalosporins).
Comments on the WHO classification of antimicrobial
agents. The WHO criteria were developed with regard only
to the importance of these antimicrobials in human medicine.
Drug classes that are not used in humans and that are currently
used only in animal medicine include arsenicals, bambermy-
cins, ionophores, orthosomycins, quinoxalines, and others. The
Office International des E´pizooties (now known as the World
Organisation for Animal Health) has undertaken a similar ini-
tiative to define critically important antimicrobial agents in
veterinary medicine.
The classification in 2005 by the WHO was the first inter-
national attempt to classify antimicrobial agents on the basis
of their importance in human medicine. The conclusions by
the WHO panel in 2005 were unanimous on all drug classi-
fications, with 1 exception [17]. There was significant discus-
sion regarding the classification of natural penicillins and ami-
nopenicillins. After thorough discussion, the consensus was that
clinicians use both types of drugs as therapy when there are
few other options for serious human disease, such as in the
case of invasive enterococcal infection. This view was reinforced
at the second WHO meeting in Copenhagen [18].
The purpose of the WHO classification is to serve as a factor
in guiding decisions regarding risk management strategies for
antimicrobial use in food animals and agriculture. Cost was
not a primary consideration in developing the list of critically
important antimicrobial agents, because there is little choice
regarding cost when an antimicrobial agent is the sole alter-
native or one of few available alternatives to treat a disease.
The list will need to be updated regularly as new information
becomes available, including data on resistance patterns, new
and emerging diseases, and new drug development. It is also
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Table 3. Important antimicrobials that are used in human medicine.
Antimicrobial class Antimicrobial(s) Criterion 1a Criterion 2b Comment(s)
Cyclic polypeptides Bacitracin No No …
Fosfomycin Fosfomycin Noc No May be 1 of limited therapies for Shiga
toxin–producing Escherichia coli O157 in certain
geographic areas
Fusidic acid Fusidic acid Noc No May be 1 of limited therapies to treat multidrug-
resistant Staphylococcus aureus infection in
certain geographic areas
Lincosamides Clindamycin and lincomycin No No …
Mupirocin Mupirocin No No …
Nitrofurantoins Furazolidone and nitrofurantoin No No …
Nitroimidazoles Metronidazole and tinidazole Noc No Criterion 1 was evaluated on the basis of antibac-
terial properties only
May be 1 of limited therapies for some anaerobic
infections, including Clostridum difficile infec-
tion, in certain geographic areas
NOTE. From the World Health Organization meeting in Copenhagen, Denmark [18]. Neither of the 2 following criteria were met for classification as an
important antimicrobial: (1) the agent or class is the sole therapy or one of few alternatives to treat serious human disease; and (2) the antimicrobial agent
or class is used to treat diseases caused by organisms that may be transmitted via nonhuman sources or diseases causes by organisms that may acquire
resistance genes from nonhuman sources.
a Criterion 1: the agent or class is the sole therapy or one of few alternatives to treat serious human disease.
b Criterion 2: the antimicrobial agent or class is used to treat diseases caused by organisms that may be transmitted via nonhuman sources or diseases
causes by organisms that may acquire resistance genes from nonhuman sources.
c The importance of the class or antimicrobial may change on the basis of regional differences.
important to take into account that antimicrobial resistance
may also develop slowly after a long period of usage. As an
example, investigators first detected vancomycin resistance in
Enterococcus after 140 years of vancomycin usage. Thus, even
if resistance has not yet developed among particular groups of
bacteria, it does not mean that it will not develop in the future.
CONCLUSION
The WHO lists are the first attempt to develop an international
consensus on the relative importance of classes of antibacterial
agents to human medicine to help guide risk management strat-
egies for use of similar agents in food animal production and
agriculture. Reducing the use of critically important antimicro-
bials in food animals will reduce the amount of resistant bac-
teria that can develop and spread. This will help mitigate a
threat to human health and decrease morbidity and mortality
in humans, by preserving effective treatments for use in the
case of serious disease caused by these bacteria. We should strive
to reduce the use of antimicrobials everywhere (and thus reduce
resistance everywhere), including reduction of inappropriate
use in humans for treatment of viral and fungal diseases, as
well as for treatment of diseases in which the benefit of anti-
bacterials is unclear (e.g., sinusitis and bronchitis). However,
these lists allow us to focus initially on those agents that are
critically important to human medicine.
The US Food and Drug Administration (FDA) has been
particularly concerned about the extra-label use of cephalo-
sporins (e.g., ceftiofur) in food animals, especially poultry [46].
The extra-label use of cephalosporins in food animals has con-
tributed to emerging cephalosporin-resistant zoonotic food-
borne bacteria. The FDA determined that extra-label use in
animals presents a risk to the public health and, therefore,
proposed a rule to prohibit the extra-label use of cephalosporins
in food animals [46]. The rule was scheduled to take effect in
November 2008, but the FDA has delayed implementation of
the final rule to review comments by various stakeholders.
However, there does not appear to be new scientific data to
alter the risks and benefits to human health with respect to the
use of cephalosporins in food-producing animals.
The same principles that were used in deriving this WHO
antibacterial ranking apply for other pathogens and the drugs
used to treat them, such as fungal diseases and antifungal
agents. It is also critical to acknowledge that most research has
involved organisms that directly cause disease, focusing less on
important contributions by commensal bacteria, which carry
antimicrobial resistance genes. Although these organisms gen-
erally do not cause disease in immunocompetent people, they
can transfer resistance genes to other bacteria. It is possible
that this phenomenon has occurred with some pathogenic bac-
teria, including S. aureus. The gene encoding methicillin resis-
tance (mecA) may have originated from less-virulent coagulase-
negative staphylococci. Horizontal transfer may occur relatively
infrequently, but once the gene is established in a successful
virulent clone, the clone and the carried gene can spread in
individual countries and worldwide, such as in the case of
multidrug-resistant S. aureus and pneumococci.
Table 4. Antimicrobial agents approved for use in human and veterinary medicine.
Category, antimicrobial class Example(s) of antimicrobials used in human medicine
Example(s) of antimicrobials used in
veterinary medicine or as growth promoters
Critically important
Aminoglycosides Amikacin, arbekacin, gentamicin, kanamycin, netilmicin, neomy-
cin, tobramycin, and streptomycin
Amikacin, apramycin, gentamicin, neomycin, strep-
tomycin, dihydrostreptomycin, kanamycin, framy-
cetin, and paromomycin (aminosidine)
Ansamycins Rifabutin, rifampin, and rifaximin Rifampicin
Carbapenems and other
penems
Ertapenem, faropenem, imipenem, meropenem, and doripenem None approved or known to be used
Cephalosporins, third
generation
Cefixime, cefotaxime, cefpodoxime, ceftazidime, ceftizoxime,
cefoperazone, cefoperazone-sulbactam, and ceftriaxone
Cefpodoxime, ceftiofur, cefoperazone, and cefovecin
Cephalosporins, fourth
generation
Cefipime, cefpirome, and cefoselis Cefquinome
Lipopeptides Daptomycin None approved or known to be used
Glycopeptides Teicoplanin and vancomycin Avoparcina
Macrolides, including 14-, 15-,
and 16-membered com-
pounds, and ketolides
Azithromycin, clarithromycin, erythromycin, midecamycin, rox-
ithromycin, spiramycin, and telithromycin
Erythromycin, pirlimycin, spiramycin, tylosin, tulath-
romycin, kitasamycin, oleandomycin, tilmicosin,
and jasamycin
Oxazolidinones Linezolid None approved or known to be used
Penicillins, aminopenicillins Ampicillin-amoxicillin, ampicillin-sulbactam, amoxicillin-clavula-
nate, piperacillin, and piperacillin-tazobactam
Ampicillin-amoxicillin, ampicillin-sulbactam, and
amoxicillin-clavulanate
Penicillins, natural Penicillin G and penicillin V Penicillin G and penicillin V
Quinolones Cinoxacin, nalidixic acid, pipedemic acid, ciprofloxacin, enoxa-
cin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin,
moxifloxacin, norfloxacin, ofloxacin, and sparfloxacin
Nalidixic acid, oxolinic acid, flumequin, pipemidic
acid, danofloxacin, difloxacin, enrofloxacin, Ibaflox-
acin, marbofloxacin, sarafloxacin, orbifloxacin, and
moxifloxacin
Streptogramins Quinupristin-dalfopristin and pristinamycin Virginiamycinb
Drugs used solely to treat tu-
berculosis or other myco-
bacterial disease
Cycloserine, ethambutol, ethionamide, isoniazid, para-aminosali-
cylic acid, and pyrazinamide
None approved or known to be used
Highly important
Cephalosporins, first
generation
Cefazolin, cephalexin, cephalothin, and cephradine Cephalothin, cephalonium, cephalexin, cefadroxil,
and cefazolin
Cephalosporins, second
generation
Cefaclor, cefamandole, cefuroxime, and loracarbef Cefuroxime
Cephamycins Cefotetan and cefoxitin None approved or known to be used
Clofazimine Clofazimine None approved or known to be used
Monobactams Aztreonam None approved or known to be used
Penicillins, aminopenicillins Mecillinam None approved or known to be used
Penicillins, antipseudomonalsa Azlocillin, carbenicillin, mezlocillin, ticarcillin, and ticarcillin-
clavulanate
None approved or known to be used
Polymyxins Polymyxin B and colistin Polymyxin B and colistin
Spectinomycin Spectinomycin Spectinomycin
Sulfonamides, dihydrofolate
reductase inhibitors, and
combinations
Para-aminobenzoic acid, pyrimethamine, sulfadiazine, sulfa-
methoxazole, sulfapyridine, sulfisoxazole, and trimethoprim
Sulfadiazine, sulfadimidime, sulfadimethoxine, tri-
methoprim, and baquiloprim
Sulfones dapsone (for treatment of leprosy) None approved or known to be used
Tetracyclines Chlortetracycline, doxycycline, minocycline, oxytetracycline, and
tetracycline
Chlortetracycline, doxycycline, oxytetracycline, and
tetracycline
Important
Amphenicols Chloramphenicol and thiophenicol Chloramphenicol, florfenicol, and thiamphenicol
Cyclic polypeptides Bacitracin Bacitracin
Fosfomycin Fosfomycin Fosfomycin
Fusidic acid Fusidic acid Fusidic acid
Lincosamides Clindamycin and lincomycin Clindamycin and lincomycin
Mupirocin Mupirocin Mupirosin
Nitrofurans Furazolidone, nitrofurantoin, and nitrofurazone Furazolidone, nitrofurantoin, and nitrofurazone
Nitroimidazoles Metronidazole and tinidazole Metronidazole and dimetridazole
Penicillins,
antistaphylococcals
Cloxacillin, dicloxacillin, flucloxacillin, methicillin, nafcillin, and
oxacillin
Cloxacillin, nafcillin, methicillin, oxacillin, and
dicloxacillin
Classes not used for human
treatment
Bambermycin None approved or known to be used Flavomycin
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Table 4. (Continued.)
Category, antimicrobial class Example(s) of antimicrobials used in human medicine
Example(s) of antimicrobials used in
veterinary medicine or as growth promoters
Novobiocin Might be some use for humans in some countries Novobiocin
Orthosomycins None approved or known to be used Avilamycin
Quinoxaline None approved or known to be used Olaquindox and carbadox
Pleuromutilins None approved or known to be used Tiamulin and valnemulin
Polyethers None approved or known to be used Monensin, salinomycin, lasalocid, and narasinc
NOTE. This table mainly includes antimicrobials approved for veterinary use in Australia, Europe, and the United States [14, 44, 45]; thus, it is not a
complete list of antimicrobials used in all countries. Extra-label use of human drugs in food animal production is also a possibility. This table was reproduced
from [13] with permission from the publisher.
a Until 2000, avoparcin was extensively used around the world (except in North America) as a growth promoter.
b Until 2000, virginiamycin was extensively used as a growth promoter in Europe. It is still used extensively in North America, Australia, and many other
parts of the world.
c Extensively used for growth promotion and/or control of coccidiosis around the world.
Antimicrobial resistance, whether attributable to animal or
human use, poses a threat to human health. The food animal
reservoir is an important source of antimicrobial resistance,
even though it might be difficult to quantify the exact burden,
compared with human use. However, to ensure the future ef-
fectiveness of antimicrobials in therapy for human disease, the
time to act is now. Protecting human health requires immediate
development and implementation of risk-management strate-
gies by government authorities for the use of fluoroquinolones,
third- and fourth-generation cephalosporins, and macrolides
in food-producing animals. The rankings provided by the
WHO can assist the risk management process so that stake-
holders can take appropriate actions that are urgently needed.
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